Cancer name Breast Cancer
Cancer Type BRCA
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment E7046
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Cell
Signature M2-like macrophages
Official Symbol M2 macrophage
Mode of action CE_D_UP
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description The ratio of M1-like/M2-like macrophages in the tumor was significantly increased by E7046+CE7777 treatment compared with vehicle or single agent treatment indicating that the E7046+CE7777 combination is able to alter the TAM populations by favoring the anti-tumor M1-like overpro-tumor M2-like TAMs.
PMID 28920002
Title EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity